Special Issue

Deubiquitylating Enzymes and Their Contribution to Human Malignancies

Message from the Guest Editor

Deubiquitinating enzymes (DUBs), a class of enzymes that remove ubiquitin or ubiquitin-like peptide chains from substrate proteins, play key roles in disease development, including cancer. Novel insights into the molecular mechanisms through which deregulated DUB expression enables cancer cells to escape cell death mechanisms, survive the tumor microenvironment, and disseminate to distant organs are beginning to emerge. In this Special Issue of Cancers, we are interested in articles reporting on the identification and/or characterization of DUBs specifically relevant to human malignancy and potentially involved in the regulation of genome maintenance mechanisms, epigenetic control, cell cycle control, DNA damage sensing and repair, and cellular death mechanisms.

Guest Editor

Dr. Tarek Abbas

Department of Radiation Oncology, University of Virginia, 1300 Jefferson Park Avenue, Charlottesville, VA, USA

Deadline for manuscript submissions

closed (31 May 2024)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/132808

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)